Business
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
SAN CARLOS, Calif., May 13, 2025--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1650,"height":310,"url":"https://media.zenfs.com/en/business-wire.com/b4bdd06b78e182bc30bcb82979b1876c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LEBuZ6TCdCDwL_qzBYBohg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b4bdd06b78e182bc30bcb82979b1876c","width":960,"height":180},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/LHyKY0y1amAkIow6iWEHqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b4bdd06b78e182bc30bcb82979b1876c","width":1200,"height":225}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., May 13, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will participate in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, with a fireside chat at 10 a.m. EDT.","length":328,"tagName":"p"},{"type":"text","content":"The live webcast of this event can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. An archived replay will be available for 1 year following the event.","length":251,"tagName":"p"},{"type":"text","content":"About BeiGene","length":13,"tagName":"p"},{"type":"text","content":"BeiGene, which will change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.","length":598,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ...